In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Union Carbide Corp.

Latest From Union Carbide Corp.

Integra's Incremental Profitability Strategy

As a small company selling into the fragmented wound care markets, Integra was spending as much as it was making. As a platform biomaterials company, Integra faced partnership risk and stood to only get a cut of end-user revenues. It needed a source of direct revenues. A year ago, the company's new CEO began building a neurosurgery business through acquisitions, initially based on mature, revenue-producing products. The strategy seems to be working; the company reached profitability in the last quarter and now holds the third position in a fragmented neurosurgery market. But the incremental strategy that has brought Integra to profitability inherently has its limitations. Now that it has created a growth expectation, it needs to achieve critical mass, through increasingly larger acquisitions or home-run products.

Medical Device Strategy

FzioMed Inc.

For several years, a handful of manufacturers has been selling biocompatible adhesion barriers aimed to separate tissues from each other during healing so that post-operative adhesions don't form between adjacent structures. FzioMed hopes to offer a cost-effective alternative to this market with a bioresorbable polymer called {Oxiplex}.

BioPharmaceutical Medical Device

Smith & Nephew: The Conservative Revolution

In the late 1980s, medical supply companies sought to leverage their relationships with new customers by creating a broad portfolio of diverse products. Smith & Nephew is pursuing a different tack--having spent a decade making one acquisition after another, it spent the last several years selling off most of those businesses. What remains is a company focused on products that repair tissue, in areas such as orthopedics, wound care, and endoscopy.

Medical Device Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Chiral Chemistry